San Diego, CA

• Cell Therapy for Type 1 Diabetes

Press

• ViaCyte Announces the Publication of a Report on Macroencapsulated Stem Cell-Derived Insulin-Producing Cells and the Issuance of Three Patents
• ViaCyte Announces Highly Anticipated Encapsulation Clinical Trial Site Expansion into Canada
• ViaCyte, Inc. Awarded $16.6 Million Accelerated Development Pathway Grant from CIRM to Expand Clinical Development of its VC-01™ Diabetes Therapy Candidate
• ViaCyte, Inc. Announces FDA Acceptance of IND to Commence Clinical Trial of VC-01™ Candidate Cell Replacement Therapy for Type 1 Diabetes
• ViaCyte, Inc. Announces Signing of Rights Agreement with Janssen Research & Development LLC.